Procept BioRobotics (PRCT)

Executive Summary

PROCEPT BioRobotics is a medical device company transforming the treatment of benign prostatic hyperplasia (BPH) through its proprietary HYDROS Robotic System and Aquablation therapy. Aquablation uses a robotic-assisted, waterjet-based approach to precisely resect prostate tissue, offering a minimally invasive alternative to traditional surgery with improved safety and efficacy. The company has established a strong commercial presence in the U.S. and is expanding internationally, driven by favorable clinical outcomes and growing surgeon adoption. With a valuation of over $1.4 billion and a public listing under ticker PRCT, PROCEPT is well-positioned to capture a significant share of the large BPH treatment market, which is underserved by current options. The company's growth trajectory is supported by a robust pipeline of clinical evidence, expanding reimbursement coverage, and strategic investments in sales and training. Recent quarters have shown accelerating procedure volumes and revenue growth, reflecting increasing acceptance of Aquablation as a standard of care. However, competition from other minimally invasive BPH therapies and the need for continued capital investment remain challenges. Overall, PROCEPT's innovative technology, strong execution, and large addressable market underpin a positive long-term outlook.

Upcoming Catalysts (preview)

• Q3 2026FDA approval for expanded indication in larger prostates70% success
• Q4 2026Positive 5-year clinical outcomes from pivotal trial85% success
• Q1 2027Commercial launch in key European markets (e.g., Germany, UK)60% success